.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
UBS
Covington
Farmers Insurance
Merck
Fish and Richardson
US Army
QuintilesIMS
Julphar
Healthtrust

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,753,679

« Back to Dashboard

Which drugs does patent 8,753,679 protect, and when does it expire?


Patent 8,753,679 protects ESBRIET and is included in one NDA.

This patent has forty-one patent family members in twenty-six countries.

Summary for Patent: 8,753,679

Title:Capsule formulation of pirfenidone and pharmaceutically acceptable excipients
Abstract: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.
Inventor(s): Radhakrishnan; Ramachandran (Fremont, CA), Vladyka; Ronald (Somerset, NJ), Sultzbaugh; Kenneth (Bridge Water, NJ)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:13/776,079
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Genentech IncESBRIETpirfenidoneCAPSULE;ORAL022535-001Oct 15, 2014RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,753,679

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,767,225Capsule formulation of pirfenidone and pharmaceutically acceptable excipients► Subscribe
8,383,150Granulate formulation of pirfenidone and pharmaceutically acceptable excipients► Subscribe
7,988,994Capsule formulation of pirfenidone and pharmaceutically acceptable excipients► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,753,679

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea101675651► Subscribe
South Korea20140029554► Subscribe
South Korea101645069► Subscribe
South Korea20130100381► Subscribe
Japan2014169341► Subscribe
Japan5715101► Subscribe
Japan2009509962► Subscribe
Japan5837732► Subscribe
Japan2012224641► Subscribe
Israel239868► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Fish and Richardson
Moodys
Dow
Fuji
Queensland Health
Citi
QuintilesIMS
US Army
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot